Skip to main content
Top
Published in: Endocrine 2/2020

01-08-2020 | Hyperuricemia and Gout | Meta-Analysis

Socioeconomic differences in hyperuricemia and gout: a systematic review and meta-analysis

Authors: Zhe Pan, Mingkai Huang, Ming Fang, Xu Xie, Ze Huang

Published in: Endocrine | Issue 2/2020

Login to get access

Abstract

Purpose

There are multiple risk factors have different influence on the disorder. However, the risk of hyperuricemia and gout in different socioeconomic status (SES) remains unclear. Recent studies provided results that contradicted to former studies. We aimed to perform a systematic review and meta-analysis of evidence to date and to assess the associations between SES and hyperuricemia or gout worldwide.

Methods

We searched MEDLINE, EMBASE, and Web of Science databases to identify studies that investigated the association between SES and hyperuricemia or gout. Studies that presented risk estimates were included. We conducted meta-analyses using random effects to combine unadjusted and adjusted effect estimates.

Results

Data from 14 studies were included, 9 provided data about hyperuricemia and 5 provided gout. Overall, there was an association between higher educational level and a higher risk of hyperuricemia (POR = 1.38, 95% CI 1.04–1.73) but lower risk of gout (POR = 0.59, 95% CI 0.47–0.71). Subgroup meta-analysis showed no association between all SES measures and hyperuricemia or gout in males or females.

Conclusions

Our study suggested that the associations between SES and hyperuricemia gout are different. Higher educational level was related to a higher risk of hyperuricemia but lower risk of gout. Given the limitations of our study, future studies are needed to investigate specific mechanisms underlying the relationship among SES differences in hyperuricemia and gout. Strategies to prevent and control SES inequalities in hyperuricemia and gout should be explored and adopted.
Appendix
Available only for authorised users
Literature
2.
go back to reference C.-F. Kuo, M.J. Grainge, W. Zhang, M. Doherty, Global epidemiology of gout: prevalence, incidence and risk factors. Nat. Rev. Rheumatol. 11, 649 (2015)CrossRefPubMed C.-F. Kuo, M.J. Grainge, W. Zhang, M. Doherty, Global epidemiology of gout: prevalence, incidence and risk factors. Nat. Rev. Rheumatol. 11, 649 (2015)CrossRefPubMed
3.
5.
go back to reference P.C. Robinson, Gout—an update of aetiology, genetics, co-morbidities and management. Maturitas 118, 67 (2018)CrossRefPubMed P.C. Robinson, Gout—an update of aetiology, genetics, co-morbidities and management. Maturitas 118, 67 (2018)CrossRefPubMed
7.
9.
go back to reference M.A. McAdams-Demarco, A. Law, J.W. Maynard, J. Coresh, A.N. Baer, Risk factors for incident hyperuricemia during mid-adulthood in African American and White men and women enrolled in the ARIC cohort study. BMC Musculoskelet. Disord. 14 (2013). https://doi.org/10.1186/1471-2474-14-347 M.A. McAdams-Demarco, A. Law, J.W. Maynard, J. Coresh, A.N. Baer, Risk factors for incident hyperuricemia during mid-adulthood in African American and White men and women enrolled in the ARIC cohort study. BMC Musculoskelet. Disord. 14 (2013). https://​doi.​org/​10.​1186/​1471-2474-14-347
18.
go back to reference R. DerSimonian, N. Laird, Meta-analysis in clinical trials. Control. Clin. Trials 7, 177–188 (1986)CrossRefPubMed R. DerSimonian, N. Laird, Meta-analysis in clinical trials. Control. Clin. Trials 7, 177–188 (1986)CrossRefPubMed
21.
go back to reference G.Schwarzer, Meta: an R package for meta-analysis. R News 7, 40–45 (2007) G.Schwarzer, Meta: an R package for meta-analysis. R News 7, 40–45 (2007)
26.
go back to reference W.G. Fang, X.M. Huang, Y. Wang, W.G. Zhu, Z.X. Bie, J.L. Chen, X.J. Zeng, A cross-sectional study of hyperuricemia in state-employees in Beijing: prevalence and risk factors.Natl Med. J. China 86, 1764–1768 (2006) W.G. Fang, X.M. Huang, Y. Wang, W.G. Zhu, Z.X. Bie, J.L. Chen, X.J. Zeng, A cross-sectional study of hyperuricemia in state-employees in Beijing: prevalence and risk factors.Natl Med. J. China 86, 1764–1768 (2006)
28.
go back to reference L. Winters-Miner, Personalized Medicine. In: L. Winters-Miner, P.S. Bolding, et al. (eds), Practical Predictive Analytics and Decisioning Systems for Medicine, pp 176–204. Academic Press (2015) L. Winters-Miner, Personalized Medicine. In: L. Winters-Miner, P.S. Bolding, et al. (eds), Practical Predictive Analytics and Decisioning Systems for Medicine, pp 176–204. Academic Press (2015)
31.
go back to reference T. Bärnighausen, D.E. Bloom, S. Humair, 3—Global health governance and tropical diseases. Presented at the (2014) T. Bärnighausen, D.E. Bloom, S. Humair, 3—Global health governance and tropical diseases. Presented at the (2014)
36.
go back to reference I. Shrier, J.-F. Boivin, R.J. Steele, R.W. Platt, A. Furlan, R. Kakuma, J. Brophy, M. Rossignol, Should meta-analyses of interventions include observational studies in addition to randomized controlled trials? Acritical examination of underlying principles. Am. J. Epidemiol. 166, 1203–1209 (2007). https://doi.org/10.1093/aje/kwm189 CrossRefPubMed I. Shrier, J.-F. Boivin, R.J. Steele, R.W. Platt, A. Furlan, R. Kakuma, J. Brophy, M. Rossignol, Should meta-analyses of interventions include observational studies in addition to randomized controlled trials? Acritical examination of underlying principles. Am. J. Epidemiol. 166, 1203–1209 (2007). https://​doi.​org/​10.​1093/​aje/​kwm189 CrossRefPubMed
Metadata
Title
Socioeconomic differences in hyperuricemia and gout: a systematic review and meta-analysis
Authors
Zhe Pan
Mingkai Huang
Ming Fang
Xu Xie
Ze Huang
Publication date
01-08-2020
Publisher
Springer US
Published in
Endocrine / Issue 2/2020
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-020-02281-w

Other articles of this Issue 2/2020

Endocrine 2/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.